Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

HISTORICAL FACTS: Lly - The Untold Story

A $2.88 Billion Reason Why Eli Lilly Stock Is in Focus Today

Eli Lilly announced a $2.88 billion acquisition of Merida Biosciences. Here’s what it means for LLY shares.

Barchart

Is Eli Lilly Stock Outperforming the Dow?

Outpacing the Dow over the past 12 months, Eli Lilly continues to receive a highly bullish outlook from Wall Street analysts, reflecting confidence in the company’s long-term prospects.

Barchart

Eli Lilly Stock: Analyst Estimates & Ratings

Eli Lilly's market-beating performance has done little to temper Wall Street's optimism, with analysts continuing to see meaningful upside in the stock.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

LLY Stock Alert: What to Know as Eli Lilly Teams Up With CVS on Weight-Loss Drugs

Eli Lilly shares rally on a fresh DTC partnership with CVS Health. A strong Q2 release and impressive future guidance is driving LLY stock higher as well.

Barchart

Stock Market Today: S&P 500, Dow Futures Gain After Scott Bessent Signals Strait of Hormuz Deal With Iran in Sight— AMD, SpaceX, SanDisk in Focus (UPDATED)

(Editor’s note: The ETFs data was updated and economic data was added.)

Benzinga

Stock Market: Will S&P 500 Open Up or Down Today?

The S&P 500 surged to a fresh record close on Tuesday as strong corporate earnings, easing oil prices and optimism over a potential breakthrough between the U.S. and Iran fueled another broad-based rally. Polymarket traders are now overwhelmingly betting the benchmark will extend those gains at Wednesday’s open.

Benzinga

Eli Lilly Could Swing $65.9 Billion After Earnings

Earnings are set to hit the tape in a tight window on Wednesday and the options market is already sketching out how much volatility traders are willing to pay for into the prints, according to Benzinga Pro.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Earnings, PMI and Other Key Things to Watch this Week

Markets enter an earnings-dominated week with a huge concentration of corporate results spanning technology, industrials, healthcare, consumer discretionary, and entertainment sectors. This will provide a critical assessment of economic health and corporate fundamentals amid persistent uncertainty about technology sector valuations and AI infrastructure spending.

Barchart

Insider Moves Are Sending Mixed Signals Across the Tech Sector

Broadcom sees insider selling after volatile 2026 trading, while Netskope draws heavy insider buying post-earnings drop and Eli Lilly CEO David Ricks purchases Adobe shares.

MarketBeat

What You Need to Know Ahead of Eli Lilly's Earnings Release

Eli Lilly will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

Barchart

Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock

Eli Lilly stock rallies on a $2.8 billion acquisition of AtaiBeckley. Here’s why the deal is bullish for LLY shares.

Barchart

AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years

While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.

Barchart

3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

MarketBeat

These 3 Quality Stocks Will Make You Want to LEAP on Their Calls

Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks stood out.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market

Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients ‌with obesity, ⁠at the ⁠American Diabetes Association meeting in New Orleans.

Barchart

Moderna Stock: Is MRNA Outperforming the Health Care Sector?

Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance on the stock’s future outlook.

MarketBeat

Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

MarketBeat

5 Best Growth Stocks for the Next 10 Years

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Eli Lilly Stock Outperforming the Nasdaq?

Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.

Barchart

Is Johnson & Johnson Stock Outperforming the Dow?

Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

Barchart

The $4 Billion Reason Eli Lilly Stock Is Up Today

Eli Lilly shares inch higher as the company announced three acquisitions for nearly $4 billion. Here’s why each of the three vaccine makers it’s buying is bullish for LLY stock.

MarketBeat

MarketBeat Week in Review – 05/18 - 05/22

Stocks were up sharply to end the week as NVIDIA’s forward guidance showed tangible demand to support AI infrastructure and overshadowed mixed retail reports

MarketBeat

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

MarketBeat

What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

Barchart

Do Wall Street Analysts Like Eli Lilly Stock?

While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.